Development and Application of an HPLC Method for Erlotinib Protein Binding Studies

Bolandnazar, Soheila; Divsalar, Adeleh; Valizadeh, Hadi; Khodaei, Arash; Zakeri–Milani, Parvin

doi:10.5681/apb.2013.047

Cited by 8 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, ascertain the Y-intercept's percentage in relation to the response at the 100% level. [13,14] The method's accuracy and recovery were assessed by determining the proportion of erlotinib and ramucirumab that were successfully recovered. Recovery tests were conducted for both medications using the usual addition approach.…”

Section: Preparation Of Working Solutionmentioning

confidence: 99%

RP-HPLC Method Development and Validation for Simultaneous Estimation of Erlotinib and Ramucirumab in bulk and Pharmaceutical Dosage form and its stability studies

Gaur,

Sahu,

Kori

2024

Int. J. Pharm. Sci. Drug Res.

View full text Add to dashboard Cite

The present study shows an easy, quick, and reliable reverse phase high performance liquid chromatography method for measuring both erlotinib and ramucirumab. For the separation and quantification, Inertsil column (150×4.6 mm, 3.5µ) is used and a mobile phase comprising acetonitrile and 0.1% formic acid (50:50) combination were utilized. A UV detector was used to locate the eluents at 236 nm, and the flow rate was 1.0 mL/min. The retention times were found to be 2.936 and 4.535 minutes, respectively. The suggested approach was validated in accordance with ICH guidelines Q2 (R1), and it was found that the linearity of the findings fell between 2.50 and 15.00 µg/mL for ramucirumab and between 37.50 and 225.00 µg/mL for erlotinib. Erlotinib and Ramucirumab demonstrated recovery rates of 99.6% and 100.1%, respectively. The robustness, accuracy, precision, and linearity range of the proposed method were all validated.

show abstract

Section: Preparation Of Working Solutionmentioning

confidence: 99%

RP-HPLC Method Development and Validation for Simultaneous Estimation of Erlotinib and Ramucirumab in bulk and Pharmaceutical Dosage form and its stability studies

Gaur,

Sahu,

Kori

2024

Int. J. Pharm. Sci. Drug Res.

View full text Add to dashboard Cite

show abstract

Carbon nanotube/polyurethane modified hollow fiber‐pencil graphite electrode for in situ concentration and electrochemical quantification of anticancer drugs Capecitabine and Erlotinib

Es’haghi

Moeinpour

2019

Engineering in Life Sciences

View full text Add to dashboard Cite

A sensitive electrochemical sensor has been designed for in situ preconcentration and determination of anticancer drugs Capecitabine (CPT) and Erlotinib hydrochloride (ETHC) based on a pencil graphite electrode modified with multivalued carbon nanotube—polyurethane (MWCNT‐PUFIX) nanocomposite that was supported with a piece of polypropylene hollow fiber (HF‐PGE). The electrochemical behavior of CPT and ETHC on the MWCNT‐PUFIX/HF‐PGE modified electrode was investigated by differential pulse voltammetry (DPV) techniques and the obtained results confirmed its efficiency for sensing of CPT and ETHC. The synthesized nanocomposite was characterized by infrared spectroscopy and scanning electron microscope. After optimization of some effective parameters on the method efficiency including pH, nanocomposite amount, the type of organic solvent, scan rate and the effect of some additives, the mentioned sensor presented suitable results for determination of CPT and ETHC with the linear ranges from 7.70 to 142.00 μM and 0.11 to 23.50 μM and detection limits of 0.11 and 0.02 μM, respectively. Also, the fabricated sensor has shown good performance in analysis of CPT and ETHC in biological samples.

show abstract

Development and Validation of the Ultraviolet Spectrophotometric Method for Determination of Erlotinib Hydrochloride

Jadav¹,

Ambasana²,

Bapodra³

2022

J Appl Spectrosc

View full text Add to dashboard Cite

Development and Application of an HPLC Method for Erlotinib Protein Binding Studies

Cited by 8 publications

References 20 publications

RP-HPLC Method Development and Validation for Simultaneous Estimation of Erlotinib and Ramucirumab in bulk and Pharmaceutical Dosage form and its stability studies

RP-HPLC Method Development and Validation for Simultaneous Estimation of Erlotinib and Ramucirumab in bulk and Pharmaceutical Dosage form and its stability studies

Carbon nanotube/polyurethane modified hollow fiber‐pencil graphite electrode for in situ concentration and electrochemical quantification of anticancer drugs Capecitabine and Erlotinib

Development and Validation of the Ultraviolet Spectrophotometric Method for Determination of Erlotinib Hydrochloride

Contact Info

Product

Resources

About